Screener
Regenxbio RGNX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $36.49M-54.1% | $15.23M-88.3% | $34.47M-40.1% | $58.8M+3.9% | $79.56M+37.7% | ||
| $69.03M-71.7% | $135.26M-1.8% | $195.6M+10.4% | $215.4M+8.3% | $243.74M+4.8% | ||
| $106.75M+429% | $10.04M-44.8% | $26.38M+28.8% | $25.35M+7.4% | $20.2M-11.4% | ||
| $236.16M-36.8% | $186.52M-40.5% | $281.28M+1.2% | $331.97M+5.9% | $373.75M+7.8% | ||
| $98.45M-11.3% | $101.87M-11.0% | $104.86M-10.8% | $107.52M-10.8% | $111.02M-10.4% | ||
| $386.62M-33.5% | $341.89M-30.4% | $453.03M-2.8% | $525.2M+1.2% | $581.03M+2.0% | ||
| $15.55M-28.2% | $21.21M+11.4% | $21.36M-6.3% | $22.27M+14.1% | $21.66M+32.3% | ||
| $9.88M-29.3% | $5.92M-56.4% | $10.45M+8,989% | $13.2M+9,063% | $13.98M+66,457% | ||
| $82.62M-30.9% | $71.11M-33.4% | $118.1M+14.4% | $124.57M+21.3% | $119.54M+21.6% | ||
| $314.85M-14.3% | $320.81M+48.0% | $350.3M+69.8% | $363.75M+67.1% | $367.35M+66.1% | ||
| $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| -$1.19B-19.7% | -$1.22B-31.3% | -$1.13B-20.8% | -$1.06B-20.2% | -$996.94M-21.4% | ||
| $71.77M-66.4% | $21.08M-92.3% | $102.73M-60.4% | $161.45M-46.4% | $213.68M-38.6% | ||
| $386.62M-33.5% | $341.89M-30.4% | $453.03M-2.8% | $525.2M+1.2% | $581.03M+2.0% |
FAQ
- What are Regenxbio's total assets?
- Regenxbio (RGNX) holds $386.6M in total assets, down 33.5% year over year.
- How much debt does Regenxbio have?
- Regenxbio carries $69.0M in total debt against $71.8M of shareholders' equity, a debt-to-equity ratio of 0.96.
- How much cash does Regenxbio have?
- Regenxbio holds $36.5M in cash and equivalents.
- Can Regenxbio cover its short-term obligations?
- Its current ratio is 2.86 — current assets exceed current liabilities.
- Where does Regenxbio's balance sheet data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
